PubRank

Fumihiko Kanai

Author PubWeight™ 75.35‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005 3.19
2 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol 2002 2.97
3 Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009 2.59
4 Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003 2.44
5 Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int 2008 2.15
6 Determination of substrate motifs for human Chk1 and hCds1/Chk2 by the oriented peptide library approach. J Biol Chem 2002 2.06
7 Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology 2008 1.88
8 Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 2005 1.65
9 Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol 2008 1.40
10 Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008 1.31
11 Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma. Clin Cancer Res 2008 1.29
12 p53-Independent negative regulation of p21/cyclin-dependent kinase-interacting protein 1 by the sonic hedgehog-glioma-associated oncogene 1 pathway in gastric carcinoma cells. Cancer Res 2005 1.25
13 Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta. Oncogene 2005 1.25
14 Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta. Oncogene 2004 1.23
15 Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochem Biophys Res Commun 2010 1.19
16 Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer. Mol Carcinog 2009 1.17
17 Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. Cancer Res 2004 1.12
18 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 2011 1.11
19 Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma. J Hepatol 2008 1.11
20 Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract. Clin Cancer Res 2006 1.09
21 Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One 2013 1.06
22 Single small-interfering RNA expression vector for silencing multiple transforming growth factor-beta pathway components. Nucleic Acids Res 2005 1.04
23 Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J Clin Gastroenterol 2008 1.03
24 Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. J Gastroenterol 2011 1.02
25 Smad4 is essential for down-regulation of E-cadherin induced by TGF-beta in pancreatic cancer cell line PANC-1. J Biochem 2007 0.99
26 Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 2005 0.99
27 Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 2014 0.99
28 Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver Int 2012 0.98
29 Analysis of the beta-catenin/T cell factor signaling pathway in 36 gastrointestinal and liver cancer cells. Jpn J Cancer Res 2002 0.98
30 Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. J Gastroenterol Hepatol 2007 0.94
31 Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magn Reson Imaging 2012 0.94
32 Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int 2011 0.92
33 Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int 2009 0.92
34 Identification of a suppressive mechanism for Hedgehog signaling through a novel interaction of Gli with 14-3-3. J Biol Chem 2009 0.91
35 A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Eur J Cancer 2013 0.91
36 TRAIL-induced cell death cooperates with IFN-gamma activation in the graft-versus-tumor effect against colon tumors. Int J Cancer 2006 0.90
37 Characterization of hepatic lesions (≤ 30 mm) with liver-specific contrast agents: a comparison between ultrasound and magnetic resonance imaging. Eur J Radiol 2012 0.89
38 Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer. Cancer Sci 2010 0.88
39 Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II. Hum Pathol 2008 0.88
40 Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015 0.87
41 Aldehyde dehydrogenase 1 is associated with recurrence-free survival but not stem cell-like properties in hepatocellular carcinoma. Hepatol Res 2012 0.87
42 Interaction of the hepatitis B virus X protein (HBx) with heat shock protein 60 enhances HBx-mediated apoptosis. Biochem Biophys Res Commun 2004 0.87
43 Proteomic analysis of the TGF-beta signaling pathway in pancreatic carcinoma cells using stable RNA interference to silence Smad4 expression. Biochem Biophys Res Commun 2004 0.87
44 Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction. Scand J Gastroenterol 2009 0.86
45 Comparison of liver biopsy and transient elastography based on clinical relevance. Can J Gastroenterol 2008 0.86
46 Macroscopic morphologic subtypes of laterally spreading colorectal tumors showing distinct molecular alterations. Int J Cancer 2010 0.85
47 Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with Lamivudine. Int J Med Sci 2013 0.85
48 Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers. Mol Carcinog 2005 0.84
49 Integrated analysis of copy number alterations and loss of heterozygosity in human pancreatic cancer using a high-resolution, single nucleotide polymorphism array. Oncology 2008 0.83
50 Rapid detection of the hepatitis B virus YMDD mutant using TaqMan-minor groove binder probes. Clin Chim Acta 2008 0.83
51 Serum fibrinogen alpha C-chain 5.9 kDa fragment as a biomarker for early detection of hepatic fibrosis related to hepatitis C virus. Proteomics Clin Appl 2013 0.82
52 Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation. J Gastroenterol 2009 0.80
53 Successful non-surgical treatment of ruptured pyogenic liver abscess. Intern Med 2013 0.80
54 Cancer-derived VEGF plays no role in malignant ascites formation in the mouse. World J Gastroenterol 2005 0.79
55 Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. J Hepatol 2011 0.79
56 Smoothened gene mutations found in digestive cancer have no aberrant Hedgehog signaling activity. J Gastroenterol 2007 0.79
57 Local ablation therapy for hepatocellular carcinoma. From ethanol injection to radiofrequency ablation. Saudi Med J 2007 0.79
58 Pretreatment microbubble-induced enhancement in hepatocellular carcinoma predicts intrahepatic distant recurrence after radiofrequency ablation. AJR Am J Roentgenol 2013 0.79
59 Natural history of large regenerative nodules and dysplastic nodules in liver cirrhosis: 28-year follow-up study. Hepatol Int 2015 0.78
60 Runx3 interacts with DNA repair protein Ku70. Exp Cell Res 2007 0.78
61 Heterogeneity of microbubble accumulation: a novel approach to discriminate between well-differentiated hepatocellular carcinomas and regenerative nodules. Ultrasound Med Biol 2012 0.77
62 Successful resection of intracranial metastasis of hepatocellular carcinoma. Case Rep Gastroenterol 2013 0.77
63 Rapid detection of mutations in the BRAF gene using real-time polymerase chain reaction and melting curve analysis. Cancer Genet Cytogenet 2004 0.77
64 Vitamin K2 binds 17beta-hydroxysteroid dehydrogenase 4 and modulates estrogen metabolism. Life Sci 2005 0.76
65 Natural history of postvascular-phase iso-enhanced lesions on the sonogram in chronic liver diseases. J Gastroenterol Hepatol 2014 0.76
66 Reduced p38 mitogen-activated protein kinase in donor grafts accelerates acute intestinal graft-versus-host disease in mice. Eur J Immunol 2005 0.76
67 Obesity did not diminish the efficacy of percutaneous ablation for hepatocellular carcinoma. Liver Int 2007 0.76
68 Simultaneous resection of disseminated hepatocellular carcinoma and colon cancer. Case Rep Gastroenterol 2013 0.75
69 Changes in plasma ghrelin and serum leptin levels after Cisplatin-based transcatheter arterial infusion chemotherapy for hepatocellular carcinoma. ISRN Gastroenterol 2013 0.75
70 A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma. Invest New Drugs 2014 0.75
71 Absence of the AKT1 pleckstrin homology domain mutation in Japanese gastrointestinal and liver cancer patients. APMIS 2008 0.75
72 Linear enhancement after radio-frequency ablation for hepatocellular carcinoma: is it a sign of recurrence? Ultrasound Med Biol 2012 0.75
73 Hepatic sarcoidosis with an increased serum level of immunoglobulin G4. Intern Med 2012 0.75
74 Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times. J Gastroenterol 2011 0.75
75 A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. Invest New Drugs 2014 0.75